Mohammad Eghbali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammad Eghbali has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amin Goodarzi
Pharmaceutical Sciences Research Center, Institute of Herbal Medicines and Metabolic Disorders, Mazandaran University of Medical Sciences, Sari 48157-33971, Iran
1 shared publication - Amirhossein Babaei
Pharmaceutical Sciences Research Center, Institute of Herbal Medicines and Metabolic Disorders, Mazandaran University of Medical Sciences, Sari 48157-33971, Iran
1 shared publication - Fereshteh Talebpour Amiri
Department of Anatomy, Faculty of Medicine, Molecular and Cell Biology Research Center Mazandaran University of Medical Sciences Sari Iran
1 shared publication - Jafar Akbari
Pharmaceutical Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication - Katayoun Morteza-Semnani
Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences
1 shared publication - Majid Saeedi
Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication
Latest Publications
- Open Access
- 15 December 2025
- Published by Scilight Press Pty Ltd in Journal of Medicinal Natural Products
- Vol. 2 (4) , 100024
Cumin Essential Oil Nanoemulgel as a Topical Analgesic and Anti-Inflammatory Alternative to NSAIDs
Cuminum cyminum L. (cumin) essential oil (CEO) possesses documented analgesic and anti-inflammatory properties, but its topical application is limited by volatility, instability and low aqueous solubility. This study aimed to develop a CEO nanoemulgel and evaluate its physicochemical characteristics, dermal safety and antinociceptive/anti-inflammatory effects in rodent models. The optimized formulation exhibited nanometric droplet size, uniform distribution and acceptable physical stability. In a rat skin irritation test, repeated application of the CEO nanoemulgel did not produce visible erythema or edema compared with the gel base. In mice, the formulation increased tail-flick latency and reduced nociceptive behaviors in both phases of the formalin test, and histological analysis revealed attenuated inflammatory cell infiltration. These findings suggest that the CEO nanoemulgel has promising antinociceptive and anti-inflammatory activity and appears to be well tolerated in short-term preclinical models. Further studies, including long-term safety assessment, mechanistic analysis and clinical trials, are required before CEO nanoemulgel can be considered for use in humans.
- 15 December 2025
- Published by Scilight Press Pty Ltd in Journal of Medicinal Natural Products
- Vol. 2 (4) , 100024
Open AccessCumin Essential Oil Nanoemulgel as a Topical Analgesic and Anti-Inflammatory Alternative to NSAIDs
Cuminum cyminum L. (cumin) essential oil (CEO) possesses documented analgesic and anti-inflammatory properties, but its topical application is limited by volatility, instability and low aqueous solubility. This study aimed to develop a CEO nanoemulgel and evaluate its physicochemical characteristics, dermal safety and antinociceptive/anti-inflammatory effects in rodent models. The optimized formulation exhibited nanometric droplet size, uniform distribution and acceptable physical stability. In a rat skin irritation test, repeated application of the CEO nanoemulgel did not produce visible erythema or edema compared with the gel base. In mice, the formulation increased tail-flick latency and reduced nociceptive behaviors in both phases of the formalin test, and histological analysis revealed attenuated inflammatory cell infiltration. These findings suggest that the CEO nanoemulgel has promising antinociceptive and anti-inflammatory activity and appears to be well tolerated in short-term preclinical models. Further studies, including long-term safety assessment, mechanistic analysis and clinical trials, are required before CEO nanoemulgel can be considered for use in humans.